Use of clopidogrel 75 mg / day of warfarin does not alter the pharmacokinetics (substrate isoenzyme CYP2C9) or MHO in patients receiving long-term treatment with warfarin.
Ukusetshenziswa kwe-clopidogrel ngomthamo we-75 mg ngosuku ayiguquki i-pharmacokinetics ye-warfarin (isakhi esingaphansi kweCYP2C9 isoenzyme) noma isilinganiso esijwayelekile samazwe omhlaba (INR) kwiziguli ezithola ukwelashwa kwesikhathi eside nge-warfarin.